PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V).

ABSTRACT:

Background

Despite the introduction of vaccination, there remains a need for pre-exposure prophylactic agents against SARS-CoV-2. Several patient groups are more vulnerable to SARS-CoV-2 infection by virtue of underlying health conditions, treatments received or suboptimal responses to vaccination.

Methods

PROTECT-V is a platform trial testing pre-exposure prophylactic interventions against SARS-CoV-2 infection in vulnerable patient populations (organ transplant recipients; individuals with oncological/haematological diagnoses, immune deficiency or autoimmune diseases requiring immunosuppression or on dialysis). Multiple agents can be evaluated across multiple vulnerable populations sharing placebo groups, with the option of adding additional treatments at later time points

SUBMITTER: Humphrey TJL 

PROVIDER: S-EPMC10009350 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature